CAPItello-291研究的简单语言摘要:Capivasertib在激素受体阳性晚期乳腺癌中
Nicholas C Turner1, Mafalda Oliveira2,3, Sacha J Howell4
1Royal Marsden Hospital, Institute of Cancer Research, London, UK.
Future oncology (London, England)
|September 16, 2024
概括
在CAPItello-291研究中发现,capivasertib加富尔韦斯兰在晚期乳腺癌患者中改善了无进展生存率. 这种组合疗法为激素受体阳性,HER2阴性晚期乳腺癌提供了一个新的选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 晚期乳腺癌,特别是激素受体阳性 (HR-阳性) 和HER2-阴性亚型,通常在初始内分泌治疗后进展.
- 先进的HR-阳性/HER2-阴性乳腺癌患者先前接受了芳酶抑制剂 (含或不含CDK4/6抑制剂) 治疗,代表了未满足医疗需求的人口.
- 在HR阳性乳腺癌中,PIK3CA/AKT1/PTEN通路经常发生改变,这使其成为新疗法的标.
研究的目的:
- 在HR-阳性/HER2-阴性晚期乳腺癌患者中,评估与安慰剂加富尔韦斯特兰特相比,与富尔韦斯特兰特联合使用的capivasertib的疗效和安全性.
- 确定PIK3CA/AKT1/PTEN通路中的基因变异对治疗结果的影响.
- 评估无进展生存期 (PFS) 作为主要终点.
主要方法:
- CAPItello-291研究是一项随机,双盲,安慰剂控制的临床试验.
- 参与者接受了capivasertib加fulvestrant或安慰剂加fulvestrant.
- 对瘤组织进行了基因改变PIK3CA,AKT1和PTEN基因的分析.
主要成果:
- 在所有参与者中,与安慰剂加富勒弗兰特相比,Capivasertib加富勒弗兰特在无进展生存期 (PFS) 呈现出统计学上显著的改善 (PFS 中位数:7.2 个月与3.6 个月).
- 在可检测到PIK3CA,AKT1和/或PTEN遗传变异的小组患者中观察到类似的PFS益处 (PFS中位数:7.3个月与3.1个月).
- 最常见的不良事件是腹和皮疹,与已知的capivasertib.形状一致.
结论:
- 卡维萨塞蒂布加富尔韦斯特兰是先进的HR阳性/HER2阴性乳腺癌患者的有效治疗选择,该癌症在先前的内分泌治疗中已经进展.
- 组合疗法在患有PIK3CA/AKT1/PTEN通路中存在特定遗传变化的瘤患者中显示出特别的益处.
- 目前正在进行的CAPItello-291研究预计将有进一步的结果.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181


